Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL 4:00:00 PM EDT
Market Cap (Intraday) | 1.12B |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $14.48 |
50-Day MA | $13.46 |
200-Day MA | $18.60 |
Zentalis Pharmaceuticals Inc Stock, NASDAQ:ZNTL
1359 Broadway, Suite 801, New York, New York 10018
United States of America
Phone: +1.212.433.3791
Number of Employees: 168
Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.